Physician profile
Mohammed Syed
NPI 1639210669
$4,293.39
in general payments reported to CMS, 2019-2025
44 companies · $570 in 2025
The $570 reported for 2025 was more than what 76% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $828 · 2020: $623 · 2021: $546 · 2022: $785 · 2023: $395 · 2024: $547 · 2025: $570.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,512.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,512.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $815.69 | 2019-2025 | Breztri, Airsupra |
| Merck Sharp & Dohme LLC | $309.03 | 2019-2025 | Verquvo |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $284.71 | 2021-2025 | Xifaxan |
| Abbvie INC. | $268.83 | 2019-2025 | Vraylar |
| Novartis Pharmaceuticals Corporation | $190.11 | 2019-2022 | |
| Pfizer INC. | $186.88 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $181.97 | 2019 | |
| Inari Medical, INC. | $171.69 | 2024 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Janssen Pharmaceuticals, INC | $167.89 | 2019-2021 | |
| Sanofi-Aventis U.S. LLC | $156.32 | 2019-2021 | |
| Nestle Healthcare Nutrition INC. | $133.85 | 2020-2021 | |
| Biosense Webster, INC. | $132.08 | 2022 | |
| Otsuka America Pharmaceutical, INC. | $117.91 | 2022-2025 | Rexulti |
| Exact Sciences Corporation | $115.18 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Hologic Sales and Service, LLC | $98.80 | 2019-2025 | Aptima, Thinprep 2000 Processor |
Show all 44 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $96.79 | 2023 | Lifevest |
| Takeda Pharmaceuticals U.S.A., INC. | $76.39 | 2023-2025 | Vpriv, Gattex |
| Bayer Healthcare Pharmaceuticals INC. | $72.91 | 2021-2022 | |
| Teleflex LLC | $53.62 | 2025 | Barrigel |
| Covidien LP | $49.49 | 2019 | |
| Amgen INC. | $49.10 | 2024-2025 | Repatha, Otezla, Repatha |
| Allergan, INC. | $37.91 | 2020 | |
| E.R. Squibb & Sons, L.L.C. | $36.71 | 2020-2021 | |
| Neurelis, INC. | $36.43 | 2021-2022 | |
| Glaxosmithkline, LLC. | $35.27 | 2022-2025 | Trelegy Ellipta |
| Alkermes, INC. | $34.81 | 2025 | Vivitrol |
| Itamar Medical INC | $34.30 | 2023 | Watchpatone |
| Vanda Pharmaceuticals INC. | $32.99 | 2025 | Fanapt |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $32.41 | 2025 | Caplyta |
| Nevro Corp. | $28.35 | 2023 | Senza |
| Chiesi USA, INC. | $23.68 | 2023 | Cleviprex |
| Alexion Pharmaceuticals, INC. | $22.62 | 2023 | Strensiq |
| Verona Pharma, INC. | $21.29 | 2025 | Ohtuvayre |
| Novo Nordisk INC | $20.99 | 2023 | Rybelsus, Ozempic |
| Abiomed | $19.05 | 2025 | |
| Kyowa Kirin, INC. | $18.80 | 2024 | Crysvita |
| Cranial Technologies, INC | $18.59 | 2024 | Doc Band |
| Amphastar Pharmaceuticals, INC. | $17.11 | 2025 | |
| Kowa Pharmaceuticals America, INC. | $17.03 | 2021 | |
| Axsome Therapeutics, INC. | $16.98 | 2023 | Auvelity |
| Abbott Laboratories | $16.64 | 2024 | Freestyle Libre 3 |
| Azurity Pharmaceuticals, INC. | $14.66 | 2025 | Edarbi |
| Phathom Pharmaceuticals, INC. | $14.65 | 2024 | Voquezna |
| Evoke Pharma, INC. | $12.88 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mohammed Syed listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.